Core Viewpoint - Acadia Healthcare is facing legal scrutiny due to allegations of violating federal securities laws, which has led to significant stock price declines and a class action lawsuit against the company [3][4][5]. Group 1: Legal Issues and Allegations - Acadia Healthcare is being investigated for claims that it held patients against their will in its facilities, even when not medically necessary, and subjected many patients to abuse [3]. - The company allegedly deceived insurance providers into covering unnecessary stays, leading to materially false and misleading statements about its business operations [3]. - A New York Times article highlighted that Acadia's practices have raised legal concerns in at least 12 states, with reports of unlawful detentions [4]. Group 2: Stock Performance and Market Reaction - Following the publication of the New York Times article, Acadia Healthcare's stock price fell by 4.5% on September 3, 2024 [4]. - On September 27, 2024, after Acadia disclosed a grand jury subpoena related to its admissions and billing practices, the stock price dropped by 16.36% [5]. Group 3: Class Action and Investor Communication - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $100,000 in Acadia Healthcare to discuss their legal options, with a deadline for lead plaintiff applications set for December 16, 2024 [1]. - The firm is also seeking information from whistleblowers and former employees regarding Acadia's conduct [6].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Agenus Inc. securities about a class action lawsuit with a lead plaintiff deadline of November 5, 2024, for those who bought shares between January 23, 2023, and July 17, 2024 [1] Group 1: Class Action Details - Investors who purchased Agenus securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 [3] Group 3: Case Allegations - The lawsuit alleges that Agenus made false and misleading statements regarding the effectiveness of its combination therapy involving botensilimab and balstilimab, overstating their clinical results and commercial prospects [4] - As a result of these misleading statements, investors suffered damages when the true details became public [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1][2]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [1]. - Shareholders who purchased shares during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, which is not required for recovery [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is November 5, 2024 [2]. Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit due to alleged misleading statements about the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is claimed that the effectiveness of the combination therapy was overstated, leading to inflated clinical results and regulatory and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is November 5, 2024, and participation does not require appointment as a lead plaintiff [2]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the case [2].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEWS ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Agenus Inc. for allegedly issuing false and misleading statements regarding the effectiveness of its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than what was communicated to investors [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Agenus Inc. for allegedly issuing false and misleading statements regarding the effectiveness of its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action lawsuit claims that the combination therapy of botensilimab and balstilimab was less effective than what was communicated to investors [1]. - The complaint alleges that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action and may seek lead plaintiff status by the deadline of November 5, 2024 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. for alleged securities fraud affecting investors between January 23, 2023, and July 17, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Agenus made false statements regarding the effectiveness of its immuno-oncology combination therapy products, botensilimab and balstilimab, which were overstated [2] - It is alleged that the clinical results and regulatory prospects of these products were misrepresented, leading to materially false and misleading public statements [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require this [2] - Class members may be entitled to compensation without any out-of-pocket costs or fees [2] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [3]

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107034&from=3  CLASS PERIOD: January 23, 2023 to July ...

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=106639&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024A ...